Dr. Reddy's Laboratories · NSE: DRREDDY · BSE: 500124
Q1 FY20 results · Apr–Jun 2019
Dr. Reddy's Laboratories reported revenue from operations of ₹3,858.20 crore (up 3.3% from Q1 FY19) and net profit of ₹676.50 crore (up 42.1% from Q1 FY19) for Q1 FY20 (Apr–Jun 2019), on a consolidated basis.
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,858.20 | 3,736.50 | +3.3% | 4,029.60 | −4.3% |
| Other income | 430.10 | 50.40 | +753.4% | 83.30 | +416.3% |
| Total income | 4,288.30 | 3,786.90 | +13.2% | 4,112.90 | +4.3% |
| Profit before share of associates & JVs and tax | 853.00 | 521.00 | +63.7% | 590.50 | +44.5% |
| Share of profit/(loss) of associates & JVs | 16.30 | 8.30 | 15.70 | ||
| Net profit for the period | 676.50 | 476.10 | +42.1% | 455.40 | +48.6% |
| EPS, basic (₹) | 40.81 | 28.69 | +42.2% | 27.45 | +48.7% |
| Net margin (%) | 17.5 | 12.7 | 11.3 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,508.70 | 2,617.60 | −4.2% | 2,645.20 | −5.2% |
| Other income | 471.40 | 34.90 | 14x | 72.70 | +548.4% |
| Total income | 2,980.10 | 2,652.50 | +12.4% | 2,717.90 | +9.6% |
| Profit before tax | 693.00 | 401.10 | +72.8% | 296.40 | +133.8% |
| Net profit for the period | 548.10 | 328.90 | +66.6% | 202.80 | +170.3% |
| EPS, basic (₹) | 33.06 | 19.82 | +66.8% | 12.22 | +170.6% |
| Net margin (%) | 21.8 | 12.6 | 7.7 |
Consolidated
- Filed with BSE
- 29 Jul 2019, 16:40 IST
- Board meeting
- 29 Jul 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 Jul 2019, 16:40 IST
- Board meeting
- 29 Jul 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE